RON

RON

RON 분자 정보

Molecule Name
Macrophage-stimulating protein receptor
분자 별명
CD136 antigen,CD136,CDw136c-met-related tyrosine kinase,EC 2.7.10,EC 2.7.10.1,macrophage stimulating 1 receptor (c-met-related tyrosine kinase),MSP R,MSP receptor,MSPR,MST1R,p185-Ron,Protein-tyrosine kinase 8,PTK8 protein tyrosine kinase 8,PTK8,Ron,RONmac
Drug Development Progress
임상 약물 수2
시판 약물 수1
최고 연구 개발 단계Approved
표적 별명
Ron tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
분자 배경
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

RON 제품 목록

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
Ningetinib TosylateCT-053-PTSA; CT-053Phase 2 ClinicalHec Pharm Co Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms
상세
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And Company
Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
CrizotinibPF-1066; PF-2341066; PF-02341066; PF-002341066ApprovedPfizer Inc赛可瑞, XalkoriUnited StatesCarcinoma, Non-Small-Cell LungPf Prism Cv2011-08-26
Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma
상세